Second-line treatment for advanced non-squamous lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This clinical trial tests a combination of two drugs—Sac-TMT (an antibody-drug conjugate that targets tumor cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)—as a second-line treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if this combination can help people whose cancer has progressed after initial chemotherapy and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-squamous non-small cell lung cancer that is advanced (stage IIIB/C or IV) and cannot be cured with surgery or radiation.
- You must not have certain genetic changes (like EGFR or ALK) that can be treated with targeted therapy.
- You must have already received a first line of treatment that included a platinum-based chemotherapy plus an immunotherapy (PD-1/PD-L1 inhibitor), and your cancer must have progressed (grown) on that treatment.
- You must have at least one measurable tumor that can be seen on scans.
- You must be in generally good health (able to care for yourself, ECOG score 0 or 1) and have adequate organ function.
- You must not have had certain previous treatments, such as anti-angiogenic drugs (like bevacizumab) or topoisomerase I inhibitors.
- You must not have severe dry eye syndrome, corneal disease, or certain eye conditions.
- You must not have active or untreated brain metastases, unless they are stable and not requiring steroids for at least 2 weeks.
- You must not have a history of interstitial lung disease (lung inflammation) or other severe lung conditions.
- You must not have active hepatitis B or C, HIV, or tuberculosis.
- You must not be pregnant or breastfeeding, and you must agree to use contraception during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, for people with EGFR-mutant lung cancer that has spread to the brain. It aims to see if this combination can shrink tumors and improve outcomes after standard EGFR inhibitor treatment has stopped working.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.